Olumiant Approved for COVID-19 Treatment in Hospitalized Adults
The FDA has approved Olumiant (baricitinib) for the treatment of COVID-19 in certain hospitalized adults.
Stay updated with breaking news from Kaplan Meier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has approved Olumiant (baricitinib) for the treatment of COVID-19 in certain hospitalized adults.
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments - read this article along with other careers information, tips and advice on BioSpace
A recent paper posted to the Public Library of Science (PLOS) ONE journal showed that plasma levels of chromogranin A (CgA) could predict death in coronavirus disease 2019 (COVID-19) patients.
Greenwich LifeSciences became public in Sept. 2020. See why I view GLSI as a Buy on weakness or a Hold, but only for those with an above-average risk tolerance.
To investigate the treatment outcomes and its determinant factors among adult patients diagnosed with selected solid malignancies at Kenyatta National Hospital.